Boehringer Ingelheim International Gmbh

Boehringer Ingelheim Vetmedica Gmbh

Viravaxx Gmbh

Viravaxx Ag

Dieter Blaas

Ernst Kuechler

Harald Mischak

Christoph Neubauer

Timothy Skern

Wolfgang Sommergruber

Ingrid Maurer-Fogy

Horst Johann Ahorn

Hans-Dieter Liebig

Rudolf Valenta

Andreas Zophel

Robert E Rhoads

Katarzyna Niespodziana

Theresia Popow-Kraupp

Barry J Lamphear

Debra Waters

Regina Kirchweger

Markus Duechler

Manfred Zorn

Elisabeth Ziegler

Friederike Fessl

Heinrich Kowalski

Peter Volkmann

Peter Pallai

Nikos Papadopoulos

Helge Torgersen

Verena Niederberger-Leppin

Johanna Edlmayr

The present invention relates to a pharmaceutical composition comprising at least one peptide consisting of a minimum of 8 and a maximum of 50 amino acid residues comprising amino acid residues 1 to 8 of a rhinovirus capsid protein selected from the group consisting of VP1, VP2, VP3 and VP4.

Method for diagnosing a rhinovirus infection

Methods of making and using Picornavirus L proteinase peptides (PLPPs) are provided, including, but not limited to, expression of DNA encoding all or a portion thereof, such as a Picornavirus L proteinase (PLP) and variants thereof, as well as methods for determining active sites and inhibitors of a PLP.

Picornavirus I proteinase and methods of making and using thereof

A substantially pure receptor with binding activity for rhinoviruses of the minor human receptor group is disclosed, which has the following characteristics:

Receptor of the minor human rhinovirus receptor group

The invention relates to the expression of mature HRV proteinase 2A, the partial purification thereof and the preparation of substrates having an inhibitory effect.

Expression of mature proteinase 2A, the partial purification thereof and

A substantially pure receptor with binding activity for rhinoviruses of the small receptor group is disclosed, which has the following characteristics:

Receptor of the small rhinovirus receptor group

The present invention relates to a method of characterizing viruses and the use thereof for classification. According to the invention, a cDNA copy of a first virus is made and the cDNA is amplified and cleaved using at least one restriction endonuclease. The location of restriction fragments is mapped and compared to that of other viruses. Primers useful for amplifying the cDNA may be derived from sequences found in the 5' non-coding regions of picornavirus including human rhinovirus.

Process for the characterization of human rhinoviruses

Receptor for the human rhinovirus minor group

This invention relates to a DNA molecule or a functional derivative thereof coding for a fusion protein, the fusion protein comprising an enzymatically active component and a non-enzymatically active polypeptide component which may be cleaved therefrom, an expression system which contains the DNA molecule, the use thereof as a test system for inhibitors of viral proteases, and an assay for identifying viral inhibitors.

Expression of the virally coded protease P2A of HRV2

Growing community of inventors

Vienna, Austria

Dieter Blaas